Apimeds Pharmaceuticals US, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| APUS | INM | LABS.TO | SHPH | ASTRAZEN.BO | DMP.F | |
|---|---|---|---|---|---|---|
| Market cap | 4.41M | 9.61M | 29.90M | 24.82M | — | 1.93B |
| P/E (TTM) | — | — | — | — | 95.1 | 14.1 |
| Forward P/E | — | -0.3 | -7.0 | — | — | 13.1 |
| Price/book | 4.5 | 0.9 | 0.8 | 0.3 | 18.4 | 3.6 |
| Dividend yield | — | — | — | — | 0.57% | 2.26% |
| 1-year change | −89.16% | −2.89% | −14.29% | −80.71% | −30.91% | +18.72% |
| Today | −1.68% | +4.17% | +16.67% | +1.17% | +1.01% | +1.17% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All APUS news ›MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure
October 09, 2026 18:00 ET | Source: MindWave Innovations Inc. MindWave Innovations Inc. MATAWAN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- globenewswire.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.